Richard Moriggl

The paper quantifies the discrepancy between population-average and single-cell suppression of pY-STAT1/3 by JAK inhibitors, showing that strong average suppression leaves many cells with elevated responses.

This study identifies TRβ as a driver of prostate cancer growth and shows that NH-3 inhibits PCa cell proliferation and tumor growth, particularly in castration-resistant models.

This study shows CD8+ T cells drive energy substrate redistribution between lymphoid organs and the heart during viral infection, with metabolic adaptations affecting cardiac function.

This study evaluates IQDMA, a multi-kinase inhibitor, as a targeted therapy for cutaneous T-cell lymphoma, showing significant tumor volume reduction and STAT3/5 pathway inhibition compared to PUVA.

The paper shows that IGF-1 reprograms bone mesenchymal stem cells in EWS::FLI1-mutant mice, leading to tumor formation, with Yap1 playing a central role, and suggests combined IGF-1R and YAP/TEAD inhibition as a potential treatment.

This study evaluates small molecule STAT3/5 inhibitors for treating AML and NKCL, showing growth arrest and synergy with existing therapies in vitro and in vivo.

This study shows JUN suppresses prostate cancer progression by inducing senescence and immune cell recruitment, with JUN depletion accelerating tumor growth.

This paper creates a mouse model with a STAT5BN642H mutation to study NK-cell leukemia and finds it leads to both indolent and aggressive forms of the disease.